Related Experiment Video

Updated: May 1, 2026

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

70.1K

Mandatory oral glucose tolerance tests identify more diabetics in stable patients with chronic heart failure: a

An Lm Stevens1, Dominique Hansen1,2, Vincent Vandoren1

  • 1REVAL Rehabilitation Research Centre, Hasselt University, Martelarenlaan 42, BE-3500 Hasselt, Belgium.

Diabetology & Metabolic Syndrome
|March 29, 2014
PubMed

Insights

Many chronic heart failure (CHF) patients have undiagnosed diabetes or prediabetes, linked to body fat distribution and heart function. Early detection through glucose tolerance tests is crucial for managing this common comorbidity.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Health

Background:

  • Undiagnosed diabetes is prevalent in chronic heart failure (CHF) patients, worsening prognosis.
  • A significant portion of stable CHF patients may have unrecognized glucose metabolism disorders.
  • Understanding glucose tolerance in CHF is vital for improving patient outcomes.

Purpose of the Study:

  • To determine the prevalence of impaired glucose tolerance in stable CHF patients.
  • To identify factors associated with glucose intolerance, focusing on body composition and muscle strength.
  • To explore the relationship between glucose metabolism and cardiac function indicators.

Main Methods:

  • Prospective observational study of stable CHF patients without glucose-lowering medication.
  • Utilized 2-hour oral glucose tolerance test (OGTT), isometric leg strength testing, and dual-energy x-ray absorptiometry (DXA).
  • Assessed quality of life and physical activity via questionnaires.

Main Results:

  • 55% prediabetic, 14% diabetic, 20% normal glucose tolerant among 56 participants.
  • Most newly diagnosed diabetics identified by 2-hour OGTT values, not HbA1c.
  • Impaired glucose tolerance correlated with fat distribution (fat trunk/fat limbs) and cardiac measures (E/E').

Conclusions:

  • A substantial majority of CHF patients exhibit impaired glucose tolerance.
  • Fat distribution and left ventricular filling pressures are key determinants of glucose intolerance in CHF.
  • These findings highlight the need for screening glucose metabolism in CHF populations.
Abstract

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.7K
Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

10.5K

Related Concept Videos

Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
25
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated...
17
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.5K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.9K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993